Disclosures for "Real Life Effectiveness and Tolerability of Cladribine Tablets (CladT) after Five Years of Treatment"
-
Antonio Pato has nothing to disclose.
-
Dr. Lorenzo Gonzalez has nothing to disclose.
-
The institution of Daniel García Estévez has received research support from MERCK. The institution of Daniel García Estévez has received research support from ROCHE.
-
Ana Lopez Real has received personal compensation in the range of $0-$499 for serving as a Consultant for Janssen. Ana Lopez Real has received personal compensation in the range of $0-$499 for serving as a Consultant for Sanofi Genzyme. Ana Lopez Real has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Genzyme. Ana Lopez Real has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck.
-
Ana Rodriguez Regal has nothing to disclose.
-
Eva Costa Arpín has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck Serono.
-
Dr. Rodriguez Rodriguez has nothing to disclose.
-
Elena Alvarez Rodriguez has nothing to disclose.
-
Author has nothing to disclose
-
Marta Aguado Valcarcel has nothing to disclose.
-
Ines Gonzalez has nothing to disclose.
-
Dr. Prieto has nothing to disclose.